Funding round
Phagos Series A
Phagos, which works in phage-based drug development in Suresnes, raised $29M in a Series A round announced on 8 Oct 2025, led by Capagro, Hoxton Ventures, CapHorn Invest and Demeter. 9 firms took part. It is Phagos' second venture round on record; the one before was a Seed in Jul 2022.
$29M
Amount raised
25,000,000 EUR converted
Not disclosed
Post-money valuation
9
Investors
4 leads
Valuation
What this round says about the price
Phagos did not disclose a valuation in this round. It came 39 months after Phagos' Seed. It is 95% of the $31M Phagos has raised in the venture rounds on record. No later venture round is on record for Phagos.
Phagos' funding rounds
Phagos has 2 venture rounds on record. This one is highlighted.
- Seed 1 Jul 2022 $1.5M
- Series A this round 8 Oct 2025, led by Capagro, Hoxton Ventures and CapHorn Invest $29M
Investors
Who put money in
Capagro, Hoxton Ventures, CapHorn Invest and Demeter led the round with 5 other firms.
Lead investors
- backs 10 venture-backed companies new investor
- Hoxton Ventures backs 50 venture-backed companies new investor
- backs 16 venture-backed companies new investor
- Demeter new investor
Also in the round
- Acurio Ventures new investor
- Citizen Capital new investor
- backs 92 venture-backed companies new investor
- backs 6 venture-backed companies new investor
- Station F new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to hiring, product development, geographic expansion, sales and marketing, scaling operations and working capital.
- Hiring
- Product development
- Geographic expansion
- Sales and marketing
- Scaling operations
- Working capital
Comparable rounds
How it compares
92 Series A rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $19M, and this round was 1.6 times the median. The closest in time, other companies' Series A rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 9 Oct 2025 | $165M | not disclosed | Sofinnova Partners and Novo Holdings |
| Pharmaceutical Products | 30 Sep 2025 | $205M | not disclosed | Novo Holdings and SR One |
| Ollin Biosciences Pharmaceutical Products | 17 Sep 2025 | $100M | not disclosed | ARCH Venture Partners and Mubadala Capital |
| Pharmaceutical Products | 5 Sep 2025 | $44M | not disclosed | not named |
| Pharmaceutical Products | 18 Nov 2025 | $37M | not disclosed | MVM Partners |
| Pharmaceutical Products | 13 Nov 2025 | $32M | $91M | not named |
| Pharmaceutical Products | 15 Sep 2025 | $14M | not disclosed | not named |
| Pharmaceutical Products | 16 Sep 2025 | $5.0M | not disclosed | not named |
Sources
Where this comes from
Reported by 5 sources.
Questions
Frequently asked
How much did Phagos raise in its Series A round?
Phagos raised $29M in its Series A round, announced in Oct 2025.
Who led Phagos' Series A round?
Capagro, Hoxton Ventures, CapHorn Invest and Demeter led it, with Acurio Ventures, Citizen Capital, Entrepreneurs First, Founders Capital and Station F.
What was Phagos' valuation at the Series A round?
It was not disclosed.
How does it compare with other Series A rounds in Pharmaceutical Products?
92 Series A rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $19M, and this round was 1.6 times the median.